Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273
Open Access
- 30 August 2021
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA
- Vol. 326 (15), 1533-1535
- https://doi.org/10.1001/jama.2021.15125
Abstract
The SARS-CoV-2 messenger RNA (mRNA) vaccines BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) have each shown more than 90% efficacy in preventing COVID-19 illness1,2 but, to our knowledge, humoral immune responses have not been compared directly.This publication has 6 references indexed in Scilit:
- In Search of the SARS-CoV-2 Protection Correlate: Head-to-Head Comparison of Two Quantitative S1 Assays in Pre-characterized Oligo-/Asymptomatic PatientsInfectious Diseases and Therapy, 2021
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infectionNature Medicine, 2021
- Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccineNature Medicine, 2021
- Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trialsThe Lancet, 2021
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineThe New England Journal of Medicine, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineThe New England Journal of Medicine, 2020